Character Biosciences, a precision medicine company focused on ophthalmology, has been selected as one of the “Fierce 15” biotechnology companies for 2025 by Fierce Biotech, according to the company.
The designation seeks to highlight private biotech firms with promising science and commercial potential. Character is cited for its integration of human genetics, longitudinal clinical data, and computational biology in pursuing therapies for age-related eye diseases.
The company’s pipeline includes two lead programs: CTX203, a lipid regulator, and CTX114, a complement inhibitor, both of which are entering Phase 1 trials. Character also maintains a drug discovery collaboration with Bausch + Lomb.
Character describes its mission as improving patient outcomes for unmet needs in dry age-related macular degeneration (AMD) and glaucoma, applying AI-driven modeling and genomic insights to enhance success rates in drug development.
Fierce Biotech has reportedly presented its “Fierce 15” list annually for 23 years to spotlight private biotechnology companies advancing transformative science.
